Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities.
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with central nervous system (CNS) disorders, has recently announced a amendment to its March 2022 ex-US royalty-based financing agreement with R-Bridge Healthcare Fund, L.P. (R-Bridge). This development repr...
Tonyco : $bluebird bio (BLUE.US)$
$X4 Pharmaceuticals (XFOR.US)$
$Edible Garden (EDBL.US)$